DelfaGLP-1 Atlas

Lead sponsor

Intarcia Therapeutics

15 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

15

Trials led

0

Active

6,012

Total enrollment

333

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 1
5
Phase 2
1
Phase 3
9

Trials by status

Completed
10
Terminated
2
Withdrawn
3

Trials led

A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650HbA1c ≥6.5%Ph 3Completed4,156
A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 DiabetesHbA1c 7.5-10.5%Ph 3Completed535
A Study to Evaluate ITCA 650 for the Treatment of Type 2 DiabetesHbA1c 7.5-10%Ph 3Completed460
Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on MetforminBMI 25-45Ph 3Terminated245
Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes MellitusHbA1c 7-10%Ph 2Completed155
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving LiraglutideBMI 25-45Ph 3Completed136
A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1cHbA1c 10-12%Ph 3Terminated100
Study of the Effects of Intravenous Exenatide on Cardiac RepolarizationBMI 19-35Ph 1Completed82
Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 DiabetesHbA1c ≥6.5%Ph 1Completed44
Study to Evaluate Pharmacokinetics of ITCA 650 in Subjects With Renal Impairment Compared to Normal SubjectsBMI 22-40Ph 1Completed38
Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied DrugsBMI 19-32Ph 1Completed33
Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female SubjectsBMI 19-32Ph 1Completed28
A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 DiabetesHbA1c 7.5-10.5%Ph 3Withdrawnnot disclosed
A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 DiabetesHbA1c 7.5-10%Ph 3Withdrawnnot disclosed
A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 DiabetesHbA1c 7.5-10.5%Ph 3Withdrawnnot disclosed